TARSUS PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances
TARSUS PHARMACEUTICALS, INC. (TARS) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances of -$17.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues · last filed 2023-11-09
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, issuances for the quarter ending 2023-03-31 was -$17.00K.
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, issuances for the quarter ending 2022-06-30 was $103.00K.
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, issuances for the quarter ending 2022-03-31 was -$245.00K.
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, issuances for fiscal 2022 was -$501.00K.
- TARSUS PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, issuances for fiscal 2021 was -$987.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Issuances 12 month as first filed |
|---|---|---|---|---|
| 2023-03-31 | -$17.00K 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | -$501.00K 10-K · filed 2023-03-17 | |||
| 2022-06-30 | $103.00K 10-Q · filed 2023-11-09 | -$142.00K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | -$245.00K 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$987.00K 10-K · filed 2023-03-17 | $1.23M 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |